CompletedEUCTR 2005-003181-41
An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesAnxiety
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Estonia and 1 more location
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 360
- Sponsor
- Sanofi-Synthelabo Recherche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Austria, Estonia, Sweden
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-003181-41
- Official title
Show the full official title
An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350...
Get this study by email
Recruitment & locations
CompletedAustria · Estonia · Sweden
Questions about this study
Who is behind this study?
The study sponsor is Sanofi-Synthelabo Recherche.
Want to explore more studies?
Explore studiesRelated studies
SEP-363856 safety and effects in adults with anxiety
A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)